Clinical trials: Depressed
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE…
- Trial name
- OPAL (NCT00326144)
- Testing
- Quetiapine fumarate
- Where
- 34 sites in United States
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00771134
- Testing
- Lu AA39959, Quetiapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- H. Lundbeck A/S
Depression, Depressive Disorder
A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model
The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a…
- Conditions
- Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
- Trial name
- FTP (NCT05685758)
- Testing
- FTP-based therapeutic mobile-app
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Hedonia Ltd
Major Depressive Disorder
Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting
- Trial name
- LEAPS (NCT00479726)
- Testing
- duloxetine hydrochloride
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Respiratory Depression
Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users.
- Trial name
- NCT03996694
- Testing
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- BioDelivery Sciences International
Mood
The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention
The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.
- Trial name
- NCT05318456
- Testing
- MoodElite T-4003-1, Comparator
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Chenland Nutritionals Inc.
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Trial name
- NCT06267846
- Testing
- NBI-1070770
- Where
- 13 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurocrine Biosciences
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Rheumatoid Arthritis
Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants
The purpose of this study is to validate standardized questionnaires on depression for RA and to investigate the frequency of depression with RA. The study will include 2 parts, VADERA I and VADERA II.
- Trial name
- NCT02485483
- Where
- 10 sites in Germany
- Volunteers
- 1,292 people
- Sponsor
- Hoffmann-La Roche
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Major Depressive Disorder
Brainsway DTMS for Treatment of MDD Using iTBS
The safety and effectiveness of the BrainsWay deep transcranial magnetic stimulation (DTMS) device for the intended use of Major Depressive Disorder (MDD) using the intermittent theta-burst (iTBS) stimulation protocol will be…
- Trial name
- NCT04679753
- Testing
- Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS), Brainsway DTMS with High Frequency (HF) Stimulation
- Where
- Canada
- Volunteers
- 177 people
- Sponsor
- Brainsway
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Treatment Resistant Depression, Depressive Disorder
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for…
- Trial name
- NCT01801319
- Testing
- Libra Deep Brain Stimulation System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Depression
Nexalin Therapy for the Treatment of Depressive Symptoms
The primary objectives of this Phase II study are to demonstrate the safety of Nexalin Therapy and to investigate the efficacy of Nexalin Therapy.
- Trial name
- NCT00774813
- Testing
- Nexalin 1.3mA Device, Nexalin 15mA device
- Where
- 2 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Kalaco Scientific, Inc.
Training of Mental Health Professionals, Training of Frontline Health Workers
Measurement-Based Peer Supervision App for Non-Specialist Providers
The goal of this project is to enhance and evaluate the efficacy of a scalable digital solution designed to help train and support the work of non-specialist providers (NSPs), such as community health workers, to deliver therapy…
- Trial name
- NCT07082010
- Testing
- MBPS App
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.